Login    Join free Add to favorites    中文
home > news > Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases

hits:382     Date:01/11/17
SAN DIEGO & HERCULES, Calif.--(BUSINESS WIRE)--Jan. 9, 2017-- Illumina, Inc. (NASDAQ:ILMN) and Bio-Rad Laboratories, Inc. (NYSE:BIO) (NYSE:BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.
 
Illumina® Bio-Rad® Single-Cell Sequencing Solution, including new ddSEQ Single-Cell Isolator (pictured with NextSeq 500) (Photo: Business Wire)
Single-cell analysis enables a deep view into the gene expression of individual cells to understand their functions in complex tissues. The solution delivers high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly, and time consuming process. Human development and disease research, fields in which single-cell sequencing is widely applicable, is expected to benefit most from this new offering.
 
鈥淪ingle-cell genomics provides the opportunity to look at stem cells turning into neurons that are lost in diseases like Parkinson鈥檚 and amyotrophic lateral sclerosis (also known as Lou Gehrig鈥檚 disease) with much higher accuracy,鈥 said Clive Svendsen, PhD, Director, Cedars-Sinai Board of Governors Regenerative Medicine Institute in Los Angeles. His laboratory tested the application of the new platform to profile single cells used in modeling neurodegenerative diseases.
 
鈥淯sing the solution made it possible to detect single cells in a population that was maturing faster than others, allowing us to produce better models of disease,鈥 added Ritchie Ho, PhD, Project Scientist in the Cedars-Sinai Board of Governors Regenerative Medicine Institute and lead researcher for the testing.
 
The solution comprises the ddSEQ™ Single-Cell Isolator and SureCell™ WTA 3鈥 Library Prep Kit. Bio-Rad鈥檚 best-in-class droplet partitioning technology, Droplet Digital™ technology, is used to isolate and barcode single cells for downstream sequencing on many of Illumina鈥檚 leading NGS instruments. The comprehensive workflow solution includes primary and secondary data analysis conducted via the BaseSpace® Informatics Suite, Illumina鈥檚 cloud-based genomics computing environment, and tertiary data analysis and visualization with SeqGeq™ from FlowJo, LLC, the market leader in flow cytometry analysis.
 
鈥淭hrough our close collaboration with Illumina we developed a seamless and scalable solution for single-cell analysis,鈥 said Annette Tumolo, Bio-Rad Executive Vice President and General Manager, Digital Biology Group. 鈥淲e are proud to equip cell biologists and others in the research community with the tools they need to power new discovery.鈥
 
鈥淏y offering cell biologists access to technologies that make single-cell analysis cost effective and easy to adopt, we hope to enable scientists to advance complex disease research using gene expression insights,鈥 said Rob Brainin, Vice President and General Manager, Applied Genomics at Illumina. 鈥淥ur collaboration with Bio-Rad has allowed us to bring this technology to market quickly and empower our customers to unlock the power of the genome to improve human health.鈥
 
The Illumina® Bio-Rad® Single-Cell Sequencing Solution will begin shipping in early February. For more information about the instruments, reagents, and workflow, visit www.bio-rad.com/ddSEQ.
 
For Research Use Only. Not for use in diagnostic procedures.
 
About Illumina
 
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
 
About Bio-Rad
 
Bio-Rad Laboratories, Inc. (NYSE: BIO) (BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com.
 
Contacts
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com
or
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Gwen Gordon
858-882-6822
pr@illumina.com
Related News>> more
advertisement

Copyright(C) 2006-2017 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙